Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia/lymphoma
Authors:
- 10 March 2020
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 99 (5) , 1093-1098
Abstract
Acute or lymphomatous type adult T cell leukemia/lymphoma (ATLL) is an aggressive hematopoietic malignancy with poor prognosis. We previously reported that programmed cell death ligand 1 (PD-L1) expression could predict ATLL outcomes. However, the roles of other immune checkpoint molecules remain largely unknown in ATLL. Our aim in this study was to explore the clinicopathological impacts of immune checkpoint molecules in ATLL. Immunohistochemistry was performed in 69 ATLL patients with antibodies against the following: PD-L1, programmed cell death ligand 2 (PD-L2), OX40, OX40 ligand (OX40L), CD137, CD137 ligand (CD137L), Galectin-9, T cell immunoglobulin mucin-3 (Tim-3), cytotoxic T lymphocyte associated protein-4 (CTLA-4), lymphocyte activating-3 (LAG-3), CD80, CD86, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), GITR ligand (GITRL), and programmed death-1 (PD-1). Immune checkpoint molecules were variably expressed on neoplastic and/or microenvironmental cells. Expression of PD-1, OX40L, Galectin-9, and PD-L1 was nearly mutually exclusive on neoplastic cells, suggesting that immune checkpoint pathways differ in patients. Microenvironmental expression of PD-L1, OX40L, and Tim-3 was significantly associated with better overall survival (log-rank test; P =0.0004, 0.0394, and 0.0279, respectively). Univariate and multivariate analyses with clinical prognostic factors identified microenvironmental expression of PD-L1 and OX40L, and age (> 70 years) as significant prognostic factors. This is the first comprehensive analysis of ATLL immune checkpoint molecules. Our results may provide information on new therapeutic strategies in ATLL.Keywords
Funding Information
- Japan Society for the Promotion of Science (JP26460446, JP17K17894)
- Japan Agency for Medical Research and Development (15ck0106015h0002)
This publication has 12 references indexed in Scilit:
- Tackling molecular targets beyond PD-1/PD-L1: Novel approaches to boost patients’ response to cancer immunotherapyCritical Reviews in Oncology/Hematology, 2019
- Ox40 regulates the conversion and suppressive function of double-negative regulatory T cellsInternational Immunopharmacology, 2018
- Role of Galectins in Tumors and in Clinical ImmunotherapyInternational Journal of Molecular Sciences, 2018
- PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphomaBlood, 2016
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune RegulationImmunity, 2016
- Rationale for anti-OX40 cancer immunotherapyEuropean Journal of Cancer, 2016
- The Evolving Role of Immune Checkpoint Inhibitors in Cancer TreatmentThe Oncologist, 2015
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- The significance of OX40 and OX40L to T‐cell biology and immune diseaseImmunological Reviews, 2009
- Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphomaBritish Journal of Haematology, 1991